← 返回前沿论文

一种新型口服含辅助表位 WT1 蛋白疫苗在小鼠白血病模型中的抗肿瘤活性增强

英文原题:Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia.

PubMed 2023/02/20(内容时间) BMC Cancer Q2 · IF 4.1(JCR 2025)

研究概要

与B. longum 420相比,B. longum 420/2656联合治疗进一步加速了依赖于肿瘤中WT1特异性CTL的抗肿瘤活性。

研究思路结论见上方概要

一种Wilms瘤1(WT1)口服疫苗,Bifidobacterium longum(B. longum)420,其中该细菌被用作WT1蛋白的载体,通过由细胞毒性T淋巴细胞(CTLs)和其他免疫活性细胞(例如辅助性T细胞)组成的细胞免疫触发免疫应答。我们开发了一种新型的、口服的、含辅助表位的WT1蛋白疫苗(B. longum 2656),以在小鼠白血病模型中检验B. longum 420/2656联合是否进一步加速CD4 + T细胞辅助增强的抗肿瘤活性。

C1498-小鼠WT1——一种经基因工程改造、表达小鼠WT1的小鼠白血病细胞系——被用作肿瘤细胞。雌性C57BL/6 J小鼠被分配至B. longum 420、2656和420/2656联合组。皮下接种肿瘤细胞当天记为第0天,第7天验证移植成功。第8天开始通过灌胃口服接种疫苗。测定肿瘤体积、外周血(PB)和TIL(肿瘤浸润淋巴细胞)(TILs)中CD8 + T细胞中WT1特异性CTL的频率和表型,以及脾细胞和TILs中经WT1 35-52肽脉冲刺激后产生干扰素-γ(INF-γ)的CD3 + CD4 + T细胞比例。

第24天,B. longum 420/2656联合组的肿瘤体积显著小于B. longum 420组(p < 0.01)。在第4周(p < 0.05)和第6周(p < 0.01),B. longum 420/2656联合组PB中CD8 + T细胞内的WT1特异性CTL频率显著高于B. longum 420组。在第4周和第6周,B. longum 420/2656联合组PB中WT1特异性效应记忆CTL的比例较B. longum 420组显著增加(各p < 0.05)。B. longum 420/2656联合组肿瘤内CD8 + T细胞中的WT1特异性CTL频率以及肿瘤内CD4 + T细胞中产生IFN-γ的CD3 + CD4 + T细胞比例均较420组显著增加(各p < 0.05)。

展开英文摘要原文

BACKGROUND: A Wilms' tumor 1 (WT1) oral vaccine, Bifidobacterium longum (B. longum) 420, in which the bacterium is used as a vector for WT1 protein, triggers immune responses through cellular immunity consisting of cytotoxic T lymphocytes (CTLs) and other immunocompetent cells (e.g., helper T cells). We developed a novel, oral, helper epitope-containing WT1 protein vaccine (B. longum 2656) to examine whether or not B. longum 420/2656 combination further accelerates the CD4 + T cell help-enhanced antitumor activity in a model of murine leukemia. METHODS: C1498-murine WT1-a genetically-engineered, murine leukemia cell line to express murine WT1-was used as tumor cell. Female C57BL/6 J mice were allocated to the B. longum 420, 2656, and 420/2656 combination groups. The day of subcutaneous inoculation of tumor cells was considered as day 0, and successful engraftment was verified on day 7. The oral administration of the vaccine by gavage was initiated on day 8. Tumor volume, the frequency and phenotypes of WT1-specific CTLs in CD8 + T cells in peripheral blood (PB) and tumor-infiltrating lymphocytes (TILs), as well as the proportion of interferon-gamma (INF-γ)-producing CD3 + CD4 + T cells pulsed with WT1 35-52 peptide in splenocytes and TILs were determined. RESULTS: Tumor volume was significantly smaller (p < 0.01) in the B. longum 420/2656 combination group than in the B. longum 420 group on day 24. WT1-specific CTL frequency in CD8 + T cells in PB was significantly greater in the B. longum 420/2656 combination group than in the B. longum 420 group at weeks 4 (p < 0.05) and 6 (p < 0.01). The proportion of WT1-specific, effector memory CTLs in PB increased significantly in the B. longum 420/2656 combination group than in the B. longum 420 group at weeks 4 and 6 (p < 0.05 each). WT1-specific CTL frequency in intratumoral CD8 + T cells and the proportion of IFN-γ-producing CD3 + CD4 + T cells in intratumoral CD4 + T cells increased significantly (p < 0.05 each) in the B. longum 420/2656 combination group than in the 420 group. CONCLUSIONS: B. longum 420/2656 combination further accelerated antitumor activity that relies on WT1-specific CTLs in the tumor compared with B. longum 420.

论文信息

作者
Minagawa H、Hashii Y、Nakajima H、Fujiki F、Morimoto S、Nakata J、Shirakawa T、Katayama T
第一作者单位
Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.Japan
通讯作者单位
Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan. yhashii@ped.med.osaka-u.ac.jp.Japan
期刊
BMC cancer2023 Feb 20
原文标识
PubMed 36803483 · DOI 10.1186/s12885-023-10547-5